Design, Synthesis, and Evaluation of Novel Quinazolin‐4(3 H )‐One Derivatives: Anti‐Leishmanial Activity, Selectivity, and Molecular Docking Insights
Journal of Biochemical and Molecular Toxicology · 2025-06 · 39 (6)
DOI: 10.1002/jbt.70309 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 18.05.2025. Verfasst von Baycan Mor und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Sciences and Letters, Kafkas University, Kars, Türkiye. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Leishmania donovani, Quinazolinones, Antiprotozoal Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: This study has been supported by Kafkas University Scientific Research Projects Coordination Unit. Project Number: 2023-FM-64, Year: 2023..
Abstract (Originalsprache)
In this study, 16 novel quinazolin‐4(3 H )‐one derivatives were synthesized and evaluated for their antileishmanial activity against Leishmania major and Leishmania donovani . Among them, compounds 2 (4‐hydroxy substituted) and 9 (4‐morpholino substituted) exhibited the highest efficacy, with compound 2 showing IC 50 values of 23.94 μM for L. major and 90.80 μM for L. donovani , while compound 9 demonstrated IC 50 values of 23.05 μM for L. major and 56.30 μM for L. donovani . Miltefosine, the reference drug, showed IC 50 values of 32.89 μM for L. major , 4.78 μM for L. donovani , and 7.53 μM for HUVEC cells. Compound 2 showed superior selectivity (SI = 15.2 for L. major and 4.0 for L. donovani ) compared to miltefosine (SI = 4.4 for L. major and 0.6 for L. donovani ). Molecular docking studies identified phosphodiesterase B1 (PDEB1) as a key target, with compound 2 showing the strongest binding affinity. The docking score of compound 2 was calculated as –11.909 kcal/mol for PDEB1. ADME predictions indicated compound 2 's favorable pharmacokinetic profile, including good solubility, permeability, and adherence to Lipinski's Rule of Five. Overall, compound 2 exhibited the most promising therapeutic profile, highlighting its potential as a lead compound for antileishmanial drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Faculty of Sciences and Letters, Kafkas University, Kars, Türkiye.
- Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Türkiye.
- Life Sciences and Technologies Application and Research Center, Kafkas University, Kars, Türkiye.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Türkiye.
- Department of Medical Parasitology, Faculty of Medicine, Kafkas University, Kars, Türkiye.
ORCID-Profile: Baycan Mor, Feyzi Sinan Tokalı, Halil Şenol
Förderung
- This study has been supported by Kafkas University Scientific Research Projects Coordination Unit. Project Number: 2023-FM-64, Year: 2023.
Zitieren
APA
Mor, B., Tokalı, F. S., Yıldız, B., Şenol, H., Aksu, Ş., & Mor, N. (2025). Design, Synthesis, and Evaluation of Novel Quinazolin‐4(3 H )‐One Derivatives: Anti‐Leishmanial Activity, Selectivity, and Molecular Docking Insights. Journal of Biochemical and Molecular Toxicology, 39(6). https://doi.org/10.1002/jbt.70309
Vancouver
Mor B, Tokalı FS, Yıldız B, Şenol H, Aksu Ş, Mor N. Design, Synthesis, and Evaluation of Novel Quinazolin‐4(3 H )‐One Derivatives: Anti‐Leishmanial Activity, Selectivity, and Molecular Docking Insights. Journal of Biochemical and Molecular Toxicology. 2025;39(6). doi:10.1002/jbt.70309
BibTeX
@article{Mor2025,
author = {Mor, Baycan and Tokalı, Feyzi Sinan and Yıldız, Barış and Şenol, Halil and Aksu, Şeyma and Mor, Neriman},
title = {Design, Synthesis, and Evaluation of Novel Quinazolin‐4(3 H )‐One Derivatives: Anti‐Leishmanial Activity, Selectivity, and Molecular Docking Insights},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
volume = {39},
number = {6},
doi = {10.1002/jbt.70309}
}
EUVIMED